Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue refers to the co-administration or combined study of Sanofi Pasteur's Tdap vaccine (Adacel) and its tetravalent dengue vaccine (Dengvaxia/CYD-TDV). Adacel is a sterile isotonic suspension of tetanus and diphtheria toxoids and adsorbed acellular pertussis antigens, used for booster immunization. Dengvaxia is a live-attenuated chimeric vaccine using a yellow fever 17D virus backbone to express the pre-membrane and envelope proteins of the four dengue virus serotypes (DENV-1, 2, 3, and 4). This combination was specifically evaluated in Phase 2 clinical trials (such as NCT00842530) to determine the safety and immunogenicity of simultaneous or sequential administration in pediatric populations in endemic regions.
- Brand names
- AdacelDengvaxia
- Other names
- Adacel + DengvaxiaTdap + CYD-TDVCYD Dengue Vaccine + Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)Fim2 (Bordetella pertussis fimbrial protein 2)Fimbrial antigen type 3
Beyond the preview
Go deeper on tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue.